These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 25655626

  • 1. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A, Chaudhry M, Blakeley JO, Wahl R.
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Derlin T, Tornquist K, Münster S, Apostolova I, Hagel C, Friedrich RE, Wedegärtner U, Mautner VF.
    Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
    [Abstract] [Full Text] [Related]

  • 3. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, O'Doherty M.
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [Abstract] [Full Text] [Related]

  • 4. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
    Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ.
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
    [Abstract] [Full Text] [Related]

  • 5. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A.
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [Abstract] [Full Text] [Related]

  • 6. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of 18F-FDG PET.
    Cook GJR, Lovat E, Siddique M, Goh V, Ferner R, Warbey VS.
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
    [Abstract] [Full Text] [Related]

  • 7. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
    Salamon J, Veldhoen S, Apostolova I, Bannas P, Yamamura J, Herrmann J, Friedrich RE, Adam G, Mautner VF, Derlin T.
    Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
    Salamon J, Derlin T, Bannas P, Busch JD, Herrmann J, Bockhorn M, Hagel C, Friedrich RE, Adam G, Mautner VF.
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):685-92. PubMed ID: 23232507
    [Abstract] [Full Text] [Related]

  • 9. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX, Cheng J, Xu WG, Dai D, Song XY, Ma WC, Zhu L, Zhu X.
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [Abstract] [Full Text] [Related]

  • 10. Value of PET in the assessment of patients with neurofibromatosis type 1.
    Bredella MA, Torriani M, Hornicek F, Ouellette HA, Plamer WE, Williams Z, Fischman AJ, Plotkin SR.
    AJR Am J Roentgenol; 2007 Oct; 189(4):928-35. PubMed ID: 17885067
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, Cronin BF, Bingham J.
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [Abstract] [Full Text] [Related]

  • 12. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
    Urban T, Lim R, Merker VL, Muzikansky A, Harris GJ, Kassarjian A, Bredella MA, Plotkin SR.
    Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
    [Abstract] [Full Text] [Related]

  • 13. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
    Reinert CP, Schuhmann MU, Bender B, Gugel I, la Fougère C, Schäfer J, Gatidis S.
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
    [Abstract] [Full Text] [Related]

  • 14. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
    Salamon J, Mautner VF, Adam G, Derlin T.
    Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
    [Abstract] [Full Text] [Related]

  • 15. Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
    Valkema MJ, Noordman BJ, Wijnhoven BPL, Spaander MCW, Biermann K, Lagarde SM, Bennink RJ, Schreurs WMJ, Roef MJ, Hobbelink MGG, Janssen MJR, Graven LH, van Lanschot JJB, Valkema R.
    J Nucl Med; 2019 Nov; 60(11):1553-1559. PubMed ID: 30877177
    [Abstract] [Full Text] [Related]

  • 16. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
    Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC.
    Cancer; 2010 Jan 15; 116(2):451-8. PubMed ID: 19924789
    [Abstract] [Full Text] [Related]

  • 17. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Ahlawat S, Blakeley JO, Rodriguez FJ, Fayad LM.
    Neurology; 2019 Sep 10; 93(11):e1076-e1084. PubMed ID: 31395668
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
    Brahmi M, Thiesse P, Ranchere D, Mognetti T, Pinson S, Renard C, Decouvelaere AV, Blay JY, Combemale P.
    PLoS One; 2015 Sep 10; 10(10):e0138386. PubMed ID: 26445379
    [Abstract] [Full Text] [Related]

  • 19. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18 F]FDG-PET imaging. Is it of value in asymptomatic patients?
    Azizi AA, Slavc I, Theisen BE, Rausch I, Weber M, Happak W, Aszmann O, Hojreh A, Peyrl A, Amann G, Benkoe TM, Wadsak W, Kasprian G, Staudenherz A, Hacker M, Traub-Weidinger T.
    Pediatr Blood Cancer; 2018 Jan 10; 65(1):. PubMed ID: 28771999
    [Abstract] [Full Text] [Related]

  • 20. Dual-phase F-18 FDG PET-CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers.
    Sürücü E, Polack BD, Demir Y, Durmuşoğlu M, Ekmekçi S, Sarıoğlu S, Çelik AO, Ada E, İkiz AÖ.
    Clin Imaging; 2015 Jan 10; 39(5):781-6. PubMed ID: 25721710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.